Danicopan (Monograph)
Brand name: Voydeya
Drug class: Complement Inhibitor Agents
Warning
Risk Evaluation and Mitigation Strategy (REMS):
FDA approved a REMS for danicopan to ensure that the benefits outweigh the risks. The REMS may apply to one or more preparations of danicopan and consists of elements to assure safe use and implementation system. See the FDA REMS page ([Web]) for specific information.
Warning
- Serious Infections Caused By Encapsulated Bacteria
-
Risk of serious infections, especially those caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B. Infections may quickly become life-threatening or fatal if not recognized and treated early.
-
Complete or update vaccination for encapsulated bacteria at least 2 weeks prior to the first dose of danicopan, unless risks of delaying therapy outweigh risk of developing a serious infection.
-
Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor.
-
Patients receiving danicopan are at increased risk for invasive disease caused by encapsulated bacteria, even if they develop antibodies following vaccination. Monitor for early signs and symptoms of serious infections; evaluate immediately if infection is suspected.
-
Because of risk of serious infections, danicopan is available only through a Risk Evaluation and Mitigation Strategy (REMS) program.
Introduction
Small molecule complement factor D inhibitor.
Uses for Danicopan
Paroxysmal Nocturnal Hemoglobinuria
Add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH); designated an orphan drug by FDA for this use. Should only be prescribed as add-on therapy to ravulizumab or eculizumab; has not been shown to be effective as monotherapy.
Options for PNH management include supportive care (e.g., iron supplementation, RBC transfusion, antibiotics for bacterial infection, anticoagulation, corticosteroids), allogeneic bone marrow transplantation, and/or terminal complement inhibitors (e.g., ravulizumab, eculizumab); choice of therapy is based on PNH classification and symptom severity.
Danicopan Dosage and Administration
General
Pretreatment Screening
-
Obtain baseline liver enzyme levels.
-
Assess immunization status prior to initiating danicopan therapy; ensure patient has received recommended vaccines.
Patient Monitoring
-
Closely monitor for early signs and symptoms of serious infection; evaluate patient immediately if infection is suspected.
-
Monitor liver enzymes periodically during treatment.
-
Monitor for signs and symptoms of hemolysis for ≥2 weeks after discontinuation.
-
Monitor serum lipid parameters periodically during treatment.
Premedication and Prophylaxis
-
Vaccinate patients against encapsulated bacteria, including Neisseria meningitidis(serogroups A, C, W, Y, and B) and Streptococcus pneumoniae according to current Advisory Committee on Immunization Practices (ACIP) recommendations ≥2 weeks prior to treatment initiation. If urgent therapy is indicated in a patient who is not up to date with these vaccines, provide antibacterial drug prophylaxis and administer the vaccines as soon as possible.
REMS
-
Because of the risk of serious infections caused by encapsulated bacteria, danicopan is available only through a restricted program called the Voydeya Risk Evaluation and Mitigation Strategy (REMS).
-
Danicopan may be prescribed only by clinicians who are enrolled in the Voydeya REMS program. Clinicians must counsel patients regarding the risk of serious infections, provide educational materials, and ensure patients are compliant with vaccinations against encapsulated bacteria and antibacterial drug prophylaxis requirements.
-
To obtain additional information or to enroll in the program, clinicians may call 1-888-765-4747 or visit [Web].
Administration
Oral Administration
Available as tablets containing 50 mg or 100 mg of danicopan.
Administer orally with or without food.
If a dose is missed, administer as soon as it is remembered unless it is within 3 hours of next scheduled dose, in which case skip the missed dose and take next dose at regularly scheduled time. Do not administer 2 or more doses at the same time.
Dosage
Adults
Paroxysmal Nocturnal Hemoglobinuria
Oral
Recommended starting dosage: 150 mg 3 times daily.
Dosage can be increased to 200 mg 3 times daily if hemoglobin level has not increased by >2 g/dL after 4 weeks of treatment, if patient required a transfusion during the previous 4 weeks, or to achieve an appropriate hemoglobin response based on clinical judgement.
Special Populations
Hepatic Impairment
No dosage adjustment required in mild to moderate hepatic impairment (Child-Pugh class A and B).
Avoid use in severe hepatic impairment.
Renal Impairment
No specific dosage recommendations at this time.
Geriatric Patients
No specific dosage recommendations at this time.
Cautions for Danicopan
Contraindications
-
Unresolved infection caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, or Haemophilus influenzaetype B.
Warnings/Precautions
Warnings
Serious Infections Caused by Encapsulated Bacteria
Risk of serious, life-threatening, or fatal infections caused by encapsulated bacteria including Neisseria meningitidis (caused by any subgroup, including non-groupable strains), Streptococcus pneumoniae, or Haemophilus influenzaetype B. (See Boxed Warning.) Infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors.
Complete or update vaccinations against encapsulated bacteria, specifically Neisseria meningitidis and Streptococcus pneumoniae ≥2 weeks prior to the first dose of danicopan, according to current Advisory Committee on Immunization Practices (ACIP) recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations considering duration of danicopan therapy.
If urgent danicopan therapy indicated in a patient not up to date with vaccines against encapsulated bacteria, provide antibacterial drug prophylaxis and administer these vaccines as soon as possible. Because optimal duration and drug regimen for prophylaxis has not been studied in unvaccinated or vaccinated patients, weigh benefits and risks of danicopan treatment and antibacterial drug prophylaxis against risks for serious infections caused by encapsulated bacteria.
Vaccination does not eliminate risk of serious encapsulated bacterial infections.
Closely monitor patients for early signs and symptoms of serious infection. Evaluate patients immediately if infection suspected.
Inform patients of signs and symptoms of infection; instruct patients to seek immediate medical care if these occur. Promptly treat known infections.
Consider interruption of danicopan in patients undergoing treatment for serious infections.
Because of risk of serious infections caused by encapsulated bacteria, danicopan is available only through a REMS program. (See REMS under Dosage and Administration.)
Other Warnings and Precautions
Hepatic Enzyme Increases
Hepatic enzyme elevations observed.
Assess liver enzymes prior to starting danicopan and periodically during treatment. Consider treatment interruption or discontinuation if clinically important elevations occur or patient is symptomatic.
Monitoring of PNH Manifestations After Treatment Discontinuation
After danicopan discontinuation, closely monitor patients for ≥2 weeks after the last dose for signs and symptoms of hemolysis. Signs and symptoms may include sudden decrease in hemoglobin or fatigue.
If danicopan discontinuation required, continue background treatment with ravulizumab or eculizumab or consider alternative therapy if necessary.
If hemolysis occurs after discontinuation, consider restarting danicopan if appropriate.
Hyperlipidemia
Increases in total cholesterol and LDL cholesterol observed.
Monitor serum lipid parameters periodically during treatment; initiate cholesterol-lowering medication, if needed.
Specific Populations
Pregnancy
No data available in pregnant individuals to evaluate for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks to mother and fetus associated with untreated PNH in pregnancy.
Use of danicopan in pregnant women or women planning to become pregnant may be considered following an assessment of risks and benefits.
Lactation
No data on presence of danicopan in human milk, effects on breast-fed children, or effects on milk production. Excreted into animal milk.
Because of potential for serious adverse reactions in breast-fed children, advise patients not to breast-feed during treatment and for 3 days after the last dose.
Pediatric Use
Safety and effectiveness not established.
Geriatric Use
Clinical studies did not include sufficient numbers of patients ≥65 years of age to determine whether they respond differently from younger adults.
Hepatic Impairment
Danicopan peak plasma concentration and AUC decreased by 27 and 8%, respectively, in patients with moderate hepatic impairment (Child-Pugh class B).
Not evaluated in severe hepatic impairment (Child-Pugh class C); avoid use.
Renal Impairment
Following oral administration in patients with severe renal impairment (eGFR <30 mL/minute per 1.73 m2), danicopan AUC increased by 52%; no clinically important change in peak plasma drug concentration or time to peak plasma concentration observed.
Common Adverse Effects
Most frequently reported adverse effect (≥10%): headache.
Drug Interactions
P-glycoprotein (P-gp) substrate. Not a substrate of breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, or OATP1B3.
Not an inducer of CYP1A2, CYP2B6, or CYP2C9. Non-CYP based metabolism is primary clearance pathway for danicopan; minimal contribution of CYP metabolism in human hepatocytes suggestive of very low likelihood of CYP-based drug interactions with danicopan.
Inhibitor of BCRP and P-gp. Does not inhibit transporters OATP1B1, OATP1B3, organic anion transporter (OAT) 1, OAT3, organic cation transporter (OCT) 2, or multidrug and toxin extrusion (MATE) 1 and MATE2-K.
Drugs Affecting or Affected by Transport Systems
BCRP Substrates
Concomitant use increases plasma concentrations of BCRP substrate, which may increase risk for adverse reactions associated with the substrate.
If used concomitantly, monitor more frequently for adverse reactions associated with BCRP substrate. Consider dosage reduction of BCRP substrate in accordance with its prescribing information.
P-gp Substrates
Concomitant use may increase plasma concentration of P-gp substrate.
Dosage adjustment may be necessary for P-gp substrates where minimal concentration changes may lead to serious adverse reactions.
Specific Drugs
Drug |
Interaction |
Comments |
---|---|---|
Antacids (calcium carbonate, aluminum/magnesium hydroxide/simethicone) |
No clinically important interaction |
|
Bupropion |
No clinically important interaction |
|
Fexofenadine (P-gp substrate) |
Danicopan dosed to steady state increased fexofenadine peak plasma concentration and AUC by 1.4-fold and 1.6-fold, respectively |
Dosage adjustment may be necessary for P-gp substrates where minimal concentration changes may lead to serious adverse reactions |
Midazolam |
No clinically important interaction |
|
Mycophenolic acid |
No clinically important interaction |
|
Omeprazole (proton pump inhibitor) |
No clinically important interaction |
|
Rosuvastatin( BCRP substrate) |
Danicopan increased rosuvastatin peak plasma concentration and AUC by 3.3-fold and 2.2-fold, respectively |
Do not exceed rosuvastatin dosage of 10 mg once daily when used concomitantly |
Tacrolimus (P-gp substrate) |
Danicopan dosed to steady state increased tacrolimus peak plasma concentration and AUC by 1.1-fold and 1.5-fold, respectively |
Dosage adjustment may be necessary for P-gp substrates where minimal concentration changes may lead to serious adverse reactions |
Warfarin |
No clinically important interaction |
Danicopan Pharmacokinetics
Absorption
Bioavailability
Exposures at steady state generally increase in a dose-proportional manner from 150 mg 3 times daily to 200 mg 3 times daily.
Systemic exposure reaches steady state in approximately 2 days. Approximately 2-fold accumulation expected at steady state following 3 times daily dosing compared to a single dose.
Median time to peak plasma concentration: 3.7 hours.
Food
Administration with high-fat meal increased AUC and peak plasma concentration by approximately 25 and 93%, respectively, compared to fasted state.
Median time to peak plasma concentration in fed or fasted state was 3 or 2.5 hours, respectively.
Distribution
Extent
Mainly distributed in plasma.
Unknown if distributed into human milk.
Plasma Protein Binding
91.5–94.3%
Elimination
Metabolism
Extensively metabolized (96%) via oxidation, reduction, and hydrolysis pathways, with amide hydrolysis being the major pathway.
Elimination Route
Fecal: 69% (3.57% as unchanged drug).
Urine: 25% (0.48% as unchanged drug).
Half-life
7.9 hours.
Special Populations
Age (16.9–82 years), sex, or race does not appear to have clinically important effects on danicopan pharmacokinetics.
Stability
Storage
Oral
Tablets, Film-Coated
20–25°C; excursions permitted to 15–30°C.
Actions
-
Small molecule complement Factor D inhibitor.
-
Binds reversibly to complement Factor D and selectively inhibits the alternative pathway (AP) of the complement system.
-
Prevents cleavage of complement Factor B into the Ba and Bb fragments, which are required for formation of the AP complement component C3 convertase (C3bBb), generation of downstream effectors including C3 fragment opsonization, and amplification of the terminal pathway.
-
Acts proximally in the AP of the complement cascade to control preferentially C3 fragment-mediated extravascular hemolysis; co-administered ravulizumab or eculizumab anticipated to maintain control over membrane attack complex-mediated intravascular hemolysis.
Advice to Patients
-
Advise patients to read the FDA-approved patient labeling (Medication Guide).
-
Advise patients of the risk of serious infections with danicopan therapy. Inform patients of the need to complete or update their vaccinations against encapsulated bacteria ≥2 weeks prior to receiving the first dose of danicopan or receive antibacterial drug prophylaxis if danicopan treatment must be initiated immediately and they have not previously been vaccinated. Inform patients of the requirement to be revaccinated according to Advisory Committee on Immunization Practices (ACIP) recommendations for encapsulated bacteria while on danicopan therapy.
-
Inform patients that vaccination may not prevent serious infection and to seek immediate medical attention if the following signs or symptoms of infection occur: fever with or without chills; fever and a rash; fever with chest pain and cough; fever with breathlessness/fast breathing; fever with high heart rate; headache with nausea or vomiting; headache with a fever; headache with a stiff neck or stiff back; confusion; body aches with flu-like symptoms; clammy skin; or eye sensitivity to light.
-
Inform patients that they will receive a Patient Safety Card for danicopan that they should carry with them at all times during treatment with danicopan and for 1 week following treatment discontinuation. Inform patients that this card describes symptoms which, if experienced, should prompt them to seek immediate medical evaluation.
-
Inform patients that danicopan is available only through a restricted program called Voydeya REMS. Inform patients of the important requirements of the program, including patient counseling and compliance with vaccinations.
-
Inform patients with paroxysmal nocturnal hemoglobinuria (PNH) of the importance of taking danicopan as prescribed to minimize the risk of hemolysis.
-
Inform patients with PNH that they may develop serious hemolysis if danicopan is discontinued and that they will be monitored by their clinicians for ≥2 weeks following treatment discontinuation.
-
Inform patients that elevation in liver enzymes have occurred in patients treated with danicopan, and liver tests will be obtained before and during treatment.
-
Inform patients that danicopan may increase cholesterol levels and that monitoring of cholesterol levels will be needed periodically during treatment.
-
Advise patients to inform their clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.
-
Advise women to inform their clinician if they are or plan to become pregnant or plan to breast-feed. Advise women not to breast-feed during treatment with danicopan, and for 3 days after the last dose.
-
Inform patients of other important precautionary information.
Additional Information
The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Oral |
Tablets, film-coated |
50 mg |
Voydeya |
Alexion Pharmaceuticals |
100 mg |
Voydeya |
Alexion Pharmaceuticals |
AHFS DI Essentials™. © Copyright 2025, Selected Revisions November 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
Reload page with references included
More about danicopan
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: selective immunosuppressants
- Breastfeeding
- En español